New Drug Combination for Advanced Lung Cancer After Previous Treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of drugs (ivonescimab with either dato-DXd or osimertinib) for people with advanced lung cancer that has a specific EGFR gene mutation and has already been treated with other therapies. The goal is to see if this combination can help control the cancer better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have biopsy-confirmed advanced lung cancer that has spread beyond the lungs (metastatic non-small cell lung cancer) with an EGFR gene mutation
- You have already received treatment with a third-generation EGFR inhibitor AND platinum-based chemotherapy (or cannot tolerate chemotherapy)
- Your cancer has at least one measurable tumor spot that hasn't been previously radiated
- You are in good overall health (ECOG performance status 0–1: able to do light activities or bedbound less than 50% of the day)
- Your blood counts, kidney function, and liver function are adequate based on lab tests
- You are 18 years or older and willing to use contraception during and after treatment (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a targeted pill (EGFR-TKI) with an antibody drug (bevacizumab) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination works better than the pill alone as a first treatment.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
This trial tests a combination of two targeted drugs (osimertinib and dalpiciclib) for people with advanced lung cancer whose tumors have a specific EGFR mutation and a change in the CDK4/6 pathway, and whose cancer has stopped responding to a third-generation EGFR targeted therapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests if adding sacituzumab tirumotecan to osimertinib works better than osimertinib alone for advanced lung cancer that still shows cancer DNA (ctDNA) in the blood after initial osimertinib treatment.
This trial tests a new combination of two drugs, osimertinib and etoposide, for people with lung cancer that has not responded well to osimertinib alone. The goal is to see if adding etoposide can help stop the cancer from growing.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.